Sagimet Biosciences Reports Q1 2026 Financial Results with Reduced Net Loss

Sagimet Biosciences Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $10.7 million, a significant reduction from the $18.2 million loss recorded in the same period of the previous year. The company’s total operating expenses decreased by 41% to $11.7 million, down from $19.9 million in Q1 2025. This decline was primarily driven by a 54% reduction in research and development expenses, which fell to $7.0 million from $15.3 million, largely due to decreased clinical trial costs associated with its lead drug candidate, denifanstat.

In terms of financial position, Sagimet's total assets decreased to $107.8 million as of March 31, 2026, compared to $116.5 million at the end of 2025. The company reported cash and cash equivalents of $36.6 million, alongside short-term marketable securities totaling $67.9 million. The accumulated deficit increased to $357.0 million, reflecting ongoing investment in research and development without any revenue from product sales, as the company remains in the clinical development stage.

Strategically, Sagimet is advancing its drug candidates, particularly denifanstat, which has shown promising results in clinical trials for treating moderate to severe acne. The company plans to file an Investigational New Drug (IND) application for denifanstat in the U.S. in mid-2026, with a registrational Phase 3 clinical trial anticipated to follow. Additionally, Sagimet is developing its second drug candidate, TVB-3567, which is currently undergoing a Phase 1 clinical trial. The company has also entered into a license agreement with Assia Chemical Industries for the development of a fixed-dose combination product involving denifanstat.

Operationally, Sagimet's employee headcount has increased as the company expands its corporate infrastructure to support its clinical programs. The company has not yet generated revenue from product sales, relying instead on financing through public and private equity and debt offerings. In April 2026, Sagimet completed an underwritten offering, raising approximately $175 million, which is expected to provide sufficient capital to fund operations for at least the next 12 months. Looking ahead, Sagimet anticipates continued investment in its research and development efforts, with a focus on advancing its drug candidates through clinical trials and seeking regulatory approvals.